Four risk prediction models have been shown to accurately select the highest risk smokers for lung cancer screening. READ MORE
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
Elderly lung cancer patients who are black or from less educated communities are less likely to get the combination of chemotherapy and radiation that’s linked to better survival odds.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.